RLYB
Rallybio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RLYB
Rallybio Corporation
A biotech company focused on developing life-changing therapies for rare diseases
Life Science Tools and Services
03/22/2018
07/29/2021
NASDAQ Stock Exchange
25
12-31
Common stock
234 Church Street, Suite 1020, New Haven, CT 06510
--
Rallybio Corporation was incorporated in Delaware on March 22, 2018. The Company is a clinical-stage biotechnology company comprised of experienced biopharmaceutical industry leaders with extensive research, development and rare disease expertise, and its mission is to develop and commercialize life-changing therapies for patients with serious and rare diseases. Since its launch in January 2018, the company has built a broad pipeline of promising product candidates designed to address diseases with unmet medical needs in areas such as maternal and fetal health, complement disorders, hematology and metabolic disorders. Two of the company's most advanced programs are in clinical development: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (" FNAIT "), and RLYB116, an inhibitor of complement component 5 (" C5 "), which has the potential to treat several complement disorder diseases.
Company Financials
EPS
RLYB has released its 2025 Q3 earnings. EPS was reported at 0.36, versus the expected -0.19, beating expectations. The chart below visualizes how RLYB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RLYB has released its 2025 Q3 earnings report, with revenue of 212.00K, reflecting a YoY change of -29.10%, and net profit of 16.02M, showing a YoY change of 239.68%. The Sankey diagram below clearly presents RLYB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
